Comparative analysis of Doxycycline and Ayurvedic herbs to target metastatic breast cancer: An in-silico approach – PubMed Black Hawk Supplements

Background: Metastasis of breast cancer cells to distant sites including lungs, liver, lymph node, brain and many more have substantially affected the overall survival outcome and distant metastasis free survival rate amongst the diseased individuals. Several pre-clinical and clinical studies were carried out to determine the potency of vigorous inhibitors but they extensively deteriorated the patient’s quality of life. Hence, there exists an urgent need to explore potent natural remedy to fight against metastatic breast cancer.

Methods: Ayurvedic medicinal plants documented in literature for their ability to fight against breast cancer was screened and their respective active moieties were evaluated to exert inhibitory effect against MMP9. Drug like efficacy of phytochemicals were determined using Molecular docking, MD Simulation, ADMET and MM-PBSA and were further compared with synthetic analogs i.e. Doxycycline.

Results: Out of 1000 phytochemicals, 12 exerted highest binding affinity (BA) even more than -9.0 kcal/mol that was significantly higher in comparison to Doxycycline which exhibited BA of -7.3 kcal/mol. In comparison to 37 × 30 × 37 Å, 53 × 45 × 66 Å offered best binding site and the highest BA was exhibited by Viscosalactone at LYS104, ASP185, MET338, LEU39, ASN38. During MD Simulation, Viscosalactone-MMP9 complex remained stable for 20 ns and the kinetic, electrostatic and potential energies were observed to be better than Doxycycline. Furthermore, Viscosalactone obtained from Withania somnifera justified the Lipinski’s Rule of 5.

Conclusion: Viscosalactone obtained from W. somnifera may act as promising drug candidate to fight against metastatic breast cancer.

1. 1. Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications Int J Mol Sci 2022. 23 6806 10.3390/ijms23126806. – DOI – PMC – PubMed
2. 1. Mittal R, Chaudhry N, Pathania S, Mukherjee TK. Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer Curr Pharmaceut Biotechnol 2014. 15 1141 57 10.2174/1389201015666141126121240. – DOI – PubMed
3. 1. Saikia M, Retnakumari AP, Anwar S, Anto NP, Mittal R, Shah S, Pillai KS, Balachandran VS, Peter V, Thomas R, Anto RJ. Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of Ras Oncotarget 2018. 9 18115 27 10.18632/oncotarget.24771. – DOI – PMC – PubMed
4. 1. Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer Br J Cancer 2021. 124 13 26 10.1038/s41416-020-01161-4. – DOI – PMC – PubMed
5. 1. Joseph C, Alsaleem M, Orah N, Narasimha PL, Miligy IM, Kurozumi S, et al. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival Breast Cancer Res Treat 2020. 182 267 82 10.1007/s10549-020-05670-x. – DOI – PMC – PubMed